Project Grant R56HL172049
Award Date
9/24/24
Completion Date
8/31/25
Dollars Obligated
$1.5M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This Project Grant award for $684,814 was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate how tissue factors in the lung modulate the inflammatory response to viral infections, and how this process suppresses alveolar stem cells in emphysema, a subtype of chronic obstructive pulmonary disease (COPD). The research utilizes novel genetic tools, human organoid platforms,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,617,792 to The Leland Stanford Junior University (Stanford University) to study the role of the carboxylesterase 1 (CES1) enzyme in the pathogenesis of pulmonary arterial hypertension (PAH). The research aims to determine how loss of CES1 leads to metabolic reprogramming, lipotoxicity, and oxidative stress in pulmonary...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $277,610 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University. The grant, awarded from Sep 1, 2024 to Aug 31, 2026, supports research to determine the role of TP53 regulation in alveolar epithelial transitional cell state and the contribution of alveolar epithelial transitional cell state to pulmonary fibrosis. The project aims to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $756,875.00 to investigate the molecular mechanisms by which neutrophil extracellular traps (NETs) contribute to airway damage and infection in mucoobstructive lung diseases. The primary focus is on understanding how NETs impact lung epithelial cells, with a specific emphasis on NET-mediated cleavage of E-cadherin and the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $607,194 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Princeton University. The grant aims to uncover the molecular, cellular, and tissue-level mechanisms connecting the planar cell polarity (PCP) component Vangl to mesenchymal thinning during the saccular stage of lung development. The research leverages innovative live-imaging, transgenic mouse models, and advanced analytical...
This $5,715,866 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop a comprehensive understanding of the early stages and progression of pulmonary fibrosis (PF), with the goal of identifying new strategies for early disease detection and prevention. The award supports four interrelated research projects and three core facilities at the University of Michigan and its sub-awardees, Vanderbilt University Medical...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $683,564.00 to The Trustees of the University of Pennsylvania to conduct research on understanding the role of alveolar epithelial stress signaling in the development of lung fibrosis. The project aims to determine how aberrant transitional epithelial cells contribute to fibrosis and to define the impact of the PERK-ISR...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $636,843 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at characterizing a targetable stromal factor that alters immune cell accumulation in the lung and defines the downstream effects of these immune cells on airway epithelial cells. The project seeks to determine the mechanism by which stromal factors in the lung...
This $203,974 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to investigate the effects of normal and diseased extracellular matrix (ECM) on the self-renewal and differentiation of airway basal epithelial cells. The project leverages novel tools developed by the co-PIs, including "inside-out" airway organoids and ECM hydrogels derived from normal and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $156,665 to The Trustees of the University of Pennsylvania to support research on regenerative processes in the lung following severe injury. The key focus is examining the role of mesenchymal cell plasticity and signaling, particularly involving Notch-mediated paracrine signaling within the alveolar niche, in driving...